HOPE-B is a clinical trial by uniQure that is investigating how well AMT-061 works to treat people with severe or moderately severe hemophilia B.

In the HOPE-B trial, we will be studying the following:
  • Factor IX activity levels over time
  • Whether AMT-061 can create enough factor IX activity to prevent bleeding episodes
  • Whether the effect of AMT-061 on bleeding episodes is similar to the effect of factor IX prophylaxis
  • Whether AMT-061 is safe
  • How long the effects of AMT-061 on factor IX activity may last
  • How other parts of your life may be impacted by AMT-061 treatment

Clinical trials are necessary to learn whether new treatment options are safe and effective. Without patients like you, clinical trials would not happen. As a trial participant, you can actively contribute to the development of new therapies for other patients in the future.

There are a lot of things to consider when deciding to enroll in a clinical trial. Keep reading to learn more about what it would be like to participate in this trial. zzz
Click here to see if you might qualifyinitbutton

What will happen during the trial?

There are 5 phases of the HOPE-B trial

To learn more, access HOPE-B here.

When we have talked about this trial with various people with hemophilia B, here were some of the questions they had…

We know you have a lot of questions. We hope we answered most of them here. Something we missed? Let us know. Contact Us

Get involved

Join us in the development of a new therapy for hemophilia B

I am a healthcare provider I am a patient
For more information, please provide the following:

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The company is developing several gene therapies for the treatment of patients with liver/metabolic, central nervous system, and other severe genetic diseases.

This website is maintained by uniQure Inc., having its offices at 113 Hartwell Avenue, Lexington, MA 02421 USA.